ZD6126 is a vascular-targeting agent and a prodrug of N-acetylcolchinol, related to colchicine.

[2] A phase I clinical trial identified gastrointestinal and cardiac effects as limiting dosing.

[3] Two phase II clinical trials were suspended investigating ZD6126 in metastatic renal cell carcinoma and metastatic colorectal cancer.

[4] ZD6126 was being investigated by AstraZeneca as a vascular disrupting agent (VDA).

However, the trials were halted, after it became apparent that ZD6126 was too cardiotoxic at the required doses.